

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 33/24	A1	(11) International Publication Number: WO 99/07387 (43) International Publication Date: 18 February 1999 (18.02.99)
(21) International Application Number: PCT/US98/16103 (22) International Filing Date: 31 July 1998 (31.07.98) (30) Priority Data: 08/908,819 8 August 1997 (08.08.97) US 09/110,511 6 July 1998 (06.07.98) US (71) Applicant: NUTRITION 21 [US/US]; Suite 335, 1010 Turquoise Street, San Diego, CA 92109 (US). (72) Inventor: MCCARTY, Mark, F.; 811B Nahant Court, San Diego, CA 92109 (US). (74) Agent: ALTMAN, Daniel, E.; Knobbe, Martens, Olson and Bear, LLP, 16th floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: CHROMIUM/BIOTIN TREATMENT OF TYPE II DIABETES (57) Abstract A method for treating Type II diabetes by administering to an affected individual a combination of chromic tripicolinate and biotin. The two compounds are administered orally or parenterally at in daily dosages which provide between 50 and 1,000 μ g of chromium and between 25 μ g and 200 mg biotin, the amounts of chromium and biotin being selected together to provide a greater than additive effect.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

CHROMIUM/BIOTIN TREATMENT OF TYPE II DIABETES

Field of the Invention

The present invention relates to the treatment of adult-onset non-insulin dependent (Type II) diabetes. More specifically, the invention relates to the treatment
5 of Type II diabetes by administering chromic picolinate and biotin.

Background of the Invention

Diabetes mellitus is known to affect at least 10 million Americans, and millions more may unknowingly have the disease. In the form of this disease known as Type II, non-insulin dependent or adult-onset (as opposed to juvenile diabetes or Type I),
10 the pancreas often continues to secrete normal amounts of insulin. However, this insulin is ineffective in preventing the symptoms of diabetes which include hyperglycemia, impaired carbohydrate metabolism, glycosuria and decreased insulin sensitivity. These symptoms, if left untreated, often lead to severe complications.

Current drugs used for managing Type II diabetes fall within two classes of
15 compounds: the biguanides and the sulfonylureas. The biguanides, e.g. metformin, are believed to prevent excessive hepatic gluconeogenesis. The sulfonylureas, e.g. tolbutamide and glyburide, lower plasma glucose primarily by stimulating insulin secretion, by enhancing insulin effects in some target tissues and by inhibiting hepatic glucose synthesis.

20 U.S. Patent 4,315,927 discloses that when selected essential metals are administered to mammals as exogenously synthesized coordination complexes of picolinic acid, they are directly available for absorption without competition from other metals. These complexes are safe, inexpensive, biocompatible and easy to produce.

25 U.S. Patent No. 5,087,623 describes the administration of chromic tripicolinate for the treatment of Type II diabetes in doses which provide between 50 and 500 μg of chromium. The U.S. Recommended Daily Allowance for chromium is 50-200 μg . Although a small decrease in glycosylated hemoglobin, an accurate indicator of blood glucose levels, was observed, the 10.4% value obtained after chromic tripicolinate
30 treatment was still within the diabetic range.

International Patent Application No. PCT/US96/06493 discloses the administration of high ("supranutritional") doses of chromium (1,000 to 10,000 µg/day) to individuals with Type II diabetes. Individuals who received 1,000 µg chromium per day as chromic tripicolinate exhibited a 30% decrease in glycosylated hemoglobin and a similar reduction in fasting and postprandial glucose levels.

Biotin is the prosthetic group for a number of carboxylation reactions, the most notable being pyruvate carboxylase which is involved in gluconeogenesis and replenishment of the citric acid cycle, and acetyl CoA carboxylase which plays a role in fatty acid biosynthesis. The safe and adequate recommended daily intake of biotin is 100-300 µg, although no side effects or toxicities were noted in previous clinical studies with oral biotin intakes of up to 200 mg daily (Mock et al, in *Present Knowledge in Nutrition*, seventh edition, Ziegler, E. et al., eds., ILSI Press, Washington, DC, 1996, pp. 220-235). Supranutritional doses of biotin have been shown to have therapeutic utility in diabetes. High-dose oral or parenteral biotin has been shown to improve oral glucose tolerance in diabetic KK mice (Reddi et al., *Life Sci.*, 42:1323-1330, 1988), rats made diabetic by injection with streptozotocin (Zhang et al., 16th International Congress of Nutrition, Montreal, 1997, abstract book, p. 264) and in pre-diabetic Otsuka Long-Evans Tokushima Fatty rats (Zhang et al., *J. Nutr. Sci. Vitaminol.* 42:517-526, 1996).

In a clinical study, Coggeshall et al. (*Ann. N.Y. Acad. Sci.*, 447:387-392, 1985) demonstrated that a daily oral dose of biotin of 16 mg lowered fasting plasma glucose levels in Type I diabetics in whom insulin injections had been temporarily discontinued. Maebashi et al. (*J. Clin. Biochem. Nutr.* 14:211-218, 1993) showed that administration of 3 mg biotin three times per day to poorly-controlled type II diabetics resulted in improved pancreatic beta cell function as evidenced by the fact that fasting insulin levels did not decline in biotin-treated subjects despite the sharp decline in glucose levels.

There is a constant need for effective treatments for type II diabetes. The present invention addresses this need by providing a safe, inexpensive, drug-free therapeutic agent.

Summary of the Invention

One embodiment of the present invention is a method for reducing hyperglycemia and stabilizing the level of serum glucose comprising administering to an individual in need thereof between about 50 and 1,000 micrograms per day of chromium as synthetic chromic tripicolinate in combination with between about 25 μ g and 200 mg per day of biotin, the amounts of chromic tripicolinate and biotin being selected together to provide a greater than additive effect. Preferably, the amount of chromium administered as synthetic chromic tripicolinate is between 500 and 1,000 micrograms per day. Advantageously, the amount of biotin administered per day is between about 1 mg and 100 mg. In one aspect of this preferred embodiment, the chromic tripicolinate is in a pharmaceutically acceptable carrier. In another aspect of this preferred embodiment, the biotin is in a pharmaceutically acceptable carrier. Preferably, the biotin is orally administered. Advantageously, the chromic tripicolinate is orally administered. Preferably, the chromic tripicolinate is parenterally administered. In another aspect of this preferred embodiment, the biotin is parenterally administered.

The present invention also provides a pharmaceutical composition comprising chromium as synthetic chromic tripicolinate and biotin, wherein the ratio of chromium to biotin is between about 2:1 and 1:200 (w/w), the amounts of chromic tripicolinate and biotin being selected together to provide a greater than additive effect.

Another embodiment of the invention is the use of synthetic chromic tripicolinate in an amount providing between about 50 and 1,000 micrograms per day of chromium in combination with between about 25 μ g and 200 mg per day of biotin for reducing hyperglycemia and stabilizing the level of serum glucose in an individual. Preferably, the synthetic chromic tripicolinate provides between about 500 and 1,000 micrograms of chromium per day. Advantageously, the biotin is present in an amount between about 1 mg and 100 mg. In one aspect of this preferred embodiment, the chromic tripicolinate and biotin are in a pharmaceutically acceptable carrier.

Detailed Description of the Preferred Embodiments

The present invention includes the discovery that doses of chromium from the highest RDA amount up to five times this amount, administered in the form of chromic picolinate, combined with either low or high doses of biotin, promote

significant reduction in blood glucose levels and stabilize blood glucose levels in individuals with type II diabetes. This reduction is markedly greater than what would be expected when either component is administered alone, thus indicating a synergistic effect.

5 The synthesis of chromic picolinate is described in U.S. 5,087,623. Chromic tripicolinate and biotin are commercially available from health food stores, drug stores and other commercial sources. In order to reduce the requirement for insulin and/or diabetic drugs and to reduce several important risk factors associated with Type II diabetes, it is anticipated that the dosage range of chromium administered to a patient
10 in the form of chromic tripicolinate will be between about 50 and 1,000 $\mu\text{g/day}$. In a preferred embodiment, this amount is between about 500 and 1,000 $\mu\text{g/day}$. With regard to the biotin component of the combination therapy, the preferred daily dosage is between about 25 μg and 200 mg. More preferably, the daily dosage of biotin is between about 1 mg and 100 mg.

15 For oral administration, the chromic picolinate and biotin may be provided as a tablet, aqueous or oil suspension, dispersible powder or granule, emulsion, hard or soft capsule, syrup or elixir. Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutically acceptable compositions and such compositions may contain one or more of the
20 following agents: sweeteners, flavoring agents, coloring agents and preservatives. The sweetening and flavoring agents will increase the palatability of the preparation. Tablets containing chromic tripicolinate in admixture with non-toxic pharmaceutically acceptable excipients suitable for tablet manufacture are acceptable. Pharmaceutically acceptable means that the agent should be acceptable in the sense of being compatible
25 with the other ingredients of the formulation (as well as non-injurious to the patient). Such excipients include inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, such as corn starch or alginic acid; binding agents such as starch, gelatin or acacia; and lubricating agents such as magnesium stearate, stearic acid or talc. Tablets may
30 be uncoated or may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a

longer period of time. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active
5 ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.

Aqueous suspensions may contain the chromic tripicolinate complex of the invention in admixture with excipients suitable for the manufacture of aqueous
10 suspensions. Such excipients include suspending agents, dispersing or wetting agents, one or more preservatives, one or more coloring agents, one or more flavoring agents and one or more sweetening agents such as sucrose or saccharin.

Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral
15 oil such as liquid paraffin. The oil suspension may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by an added antioxidant such as ascorbic acid. Dispersible powders and granules of the invention suitable for preparation of an
20 aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

Syrups and elixirs may be formulated with sweetening agents, such as glycerol,
25 sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.

The chromic tripicolinate preparations for parenteral administration may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to methods well
30 known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or

suspension in a non-toxic parenterally-acceptable diluent or solvent, such as a solution in 1,3-butanediol. Suitable diluents include, for example, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils may be employed conventionally as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono or diglycerides. In addition, fatty acids such as oleic acid may likewise be used in the preparation of injectable preparations.

The pharmaceutical compositions may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil such as liquid paraffin, or a mixture thereof. Suitable emulsifying agents include naturally-occurring gums such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan mono-oleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan mono-oleate. The emulsions may also contain sweetening and flavoring agents.

The amount of chromic tripicolinate/biotin that may be combined with the carrier material to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

The above description of the invention is set forth solely to assist in understanding the invention. It is to be understood that variations of the invention, including all equivalents now known or later developed, are to be considered as falling within the scope of the invention, which is limited only by the following claims.

WHAT IS CLAIMED IS:

1. A method for reducing hyperglycemia and stabilizing the level of serum glucose comprising administering to an individual in need thereof between about 50 and 1,000 micrograms per day of chromium as synthetic chromic tripicolinate in combination with between about 25 μ g and 200 mg per day of biotin, wherein the amounts of chromic tripicolinate and biotin are selected together to provide a greater than additive effect.
2. The method of Claim 1, comprising administering between about 500 and 1,000 micrograms per day of chromium as synthetic chromic tripicolinate.
3. The method of Claim 1, comprising administering between about 1 mg and 100 mg biotin per day.
4. The method of Claim 1, wherein said chromic tripicolinate is in a pharmaceutically acceptable carrier.
5. The method of Claim 1, wherein said biotin is in a pharmaceutically acceptable carrier.
6. The method of Claim 1, wherein said chromic tripicolinate is orally administered.
7. The method of Claim 1, wherein said biotin is orally administered.
8. The method of Claim 1, wherein said chromic tripicolinate is parenterally administered.
9. The method of Claim 1, wherein said biotin is parenterally administered.
10. A pharmaceutical composition comprising chromium as synthetic chromic tripicolinate and biotin, wherein the ratio of chromium to biotin is between about 2:1 and 1:200 (w/w), wherein the amounts of chromic tripicolinate and biotin are selected together to provide a greater than additive effect.
11. Use of synthetic chromic tripicolinate in an amount providing between about 50 and 1,000 micrograms per day of chromium in combination with between about 25 μ g and 200 mg per day of biotin for reducing hyperglycemia and stabilizing the level of serum glucose in an individual.
12. The use of Claim 11, wherein said synthetic chromic tripicolinate provides between about 500 and 1,000 micrograms of chromium per day.

13. The use of Claim 11, wherein said biotin is present is an amount between about 1 mg and 100 mg.

14. The use of Claim 11, wherein said chromic tripicolinate and said biotin are in a pharmaceutically acceptable carrier.

5

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/16103

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K33/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	ANDERSON: "Nutritional Factors Influencing the Glucose/Insulin System: Chromium" JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, vol. 16, no. 5, October 1997, pages 404-410, XP002086777 see page 405, right-hand column, paragraph 3 see page 408, left-hand column, paragraph 2	1,2,4, 10-12,14
X	US 5 597 585 A (WILLIAMS ANDREW H ET AL) 28 January 1997 see column 2, line 63 - column 3, line 10 see column 5, line 64-66 --- -/--	10,11, 13,14



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

4 December 1998

Date of mailing of the international search report

21/12/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kanbier, D

INTERNATIONAL SEARCH REPORT

Internal Application No

PCT/US 98/16103

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	WO 91 11117 A (UNIV TEXAS) 8 August 1991 see page 21, paragraph 4 - page 22, paragraph 1; claims 3,4 see page 24, paragraph 4 see page 28, paragraph 3 ---	10,11,14 1-7,12, 13
X A	WO 96 25939 A (SABINSA CORP) 29 August 1996 see claims 1,6,11; examples 7,9,10 ---	10,14 1-7, 11-13
X	US 5 470 846 A (SANDYK REUVEN) 28 November 1995 see column 8, line 11-20 see column 8, line 52-54 see column 9, line 1-2 ---	10,14
X	US 5 496 827 A (PATRICK JAY) 5 March 1996 see example 1 ---	10,14
X	US 5 635 535 A (WAGSTAFF ROBERT K) 3 June 1997 see column 5, line 45 - column 6, line 30 ---	10,14
X	US 5 336 672 A (SOUTHERN JR LINCOLN L ET AL) 9 August 1994 see column 3, line 33-35; claims 1-6; table 1 ---	10,14
Y	MAEBASHI ET AL: "Therapeutic Evaluation of the Effect of Biotin on Hyperglycemia in Patients with NIDDM" J CLIN BIOCHEM NUTR, vol. 14, no. 3, 1993, pages 211-218, XP002086778 cited in the application see page 212, paragraph 2 - page 213, paragraph 1 ---	1-5,7, 10-14
Y	RAVINA ET AL: "Clinical Use of the Trace Element Chromium (III) in the Treatment of Diabetes Mellitus" JOURNAL OF TRACE ELEMENTS IN EXPERIMENTAL MEDICINE, vol. 8, no. 3, 1995, pages 183-190, XP002086779 see page 184, paragraph 1 see page 184, paragraph 2 - page 185 see page 189 ---	1-5,7, 10-14

-/--

INTERNATIONAL SEARCH REPORT

Inter. Application No.
PCT/US 98/16103

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MCCARTY: "The Case for Supplementation Chromium and a Survey of Clinical Studies with Chromium Picolinate" JOURNAL OF APPLIED NUTRITION, vol. 43, no. 1, 1991, pages 58-66, XP000600695 see page 62, left-hand column, paragraph 3 - page 63, left-hand column, paragraph 3 ---	1-5,7, 10-14
A	CEFALU ET AL: "The Effect of Chromium Supplementation on Carbohydrate Metabolism and Body Fat Distribution" DIABETES, vol. 46, no. suppl, May 1997, page 55a XP002086780 see abstract -----	1,2, 10-12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/16103

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5597585	A	28-01-1997	NONE	
WO 9111117	A	08-08-1991	AT 147592 T	15-02-1997
			AU 646840 B	10-03-1994
			AU 7241491 A	21-08-1991
			CA 2074527 A	06-08-1991
			DE 69124223 D	27-02-1997
			DE 69124223 T	30-04-1997
			EP 0514451 A	25-11-1992
WO 9625939	A	29-08-1996	US 5536506 A	16-07-1996
			US 5744161 A	28-04-1998
			AU 4128796 A	11-09-1996
			EP 0810868 A	10-12-1998
US 5470846	A	28-11-1995	US 5691324 A	25-11-1997
			US 5691325 A	25-11-1997
US 5496827	A	05-03-1996	NONE	
US 5635535	A	03-06-1997	NONE	
US 5336672	A	09-08-1994	NONE	